Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Markets News, January 17, 2025: Stocks Surge as Big-Tech Rallies; S&P 500 Has Best Week in Two Months; Bitcoin Tops $105,000 ...